In 2006, Frasci et al. published in Annals of Oncology the final analysis of a Southern Italy Oncology Cooperative Group (SICOG) phase III study that compared weekly cycles of the dosedense cisplatin-epirubicin-paclitaxel (PET) chemotherapy regimen with triweekly cycles of epirubicin-paclitaxel in locally advanced breast cancer. Pathological complete response (pCR) was designed as the main end point [1] .
Four years later, an update of this trial is published in the same journal [2] . This analysis focuses on relapse-free survival (RFS), distant metastasis-free survival (DMFS) and overall survival (OS). These last results merit particular consideration as they present a previously unpublished large and statistically significant improvement of both DMFS and OS in favour of a platinum-containing dose-dense regimen in a (neo)adjuvant setting. However, a major pitfall is that it was neither DMFS nor OS that was the primary end point of this phase III study, but pCR. Did Frasci et al. choose the appropriate end point?
High prognostic value of major response to preoperative chemotherapy in breast carcinoma has been described 25 years ago [3] . The high correlation between pCR (mainly both within the breast and within the axillary lymph nodes) and long-term outcome was confirmed by other groups in univariate and multivariate analyses [4, 5] . Coupled with the ease of obtaining information at a fixed and early date after patient inclusion, achievement of pCR has become a widely used end point for clinical research in neoadjuvant settings.
Since the introduction of the neoadjuvant strategy in daily practice, at least a dozen pathological response classifications have been proposed. The first ones were primarily on the basis of final pathological assessments of residual disease on posttreatment surgical bed specimens. The strong prognostic value of residual disease in axillary lymph nodes has been highlighted [6] , while it has been shown that residual ductal in situ components in tumour beds do not have prognostic significance [7] . During the last 3 years, four new pathological classifications have been described taking into account pretreatment staging, either clinically [8] , or using breast contrast-enhanced magnetic resonance imaging and axillary ultrasonography [9] or by bidimensional measurement of the primary bed in the resection specimen [10] . A 'neoadjuvant response index' estimating the degree of downstaging achieved by the neoadjuvant treatment has been developed in order to compare the efficacy of different neoadjuvant regimens and to evaluate the sensitivity of tumour subtypes to a specific drug [9] . Moreover, new classifications have tried to better assess residual disease either quantitatively or by considering its residual aggressiveness. Residual cellularity in the tumour bed chosen for the 'residual cancer burden' may better quantify residual disease than residual tumour size [10] , especially in the case of scattered patterns of scarring induced by the chemotherapy. Interestingly, in patients not achieving a pCR, both pre-and post-therapy Ki-67 and Scarff-BloomRichardson (SBR) grading retain their prognostic significance in the case of neoadjuvant chemotherapy. In comparison with pretreatment values, post-treatment analyses are more informative [11, 12] . For instance, in Jones' series, 5-year RFS was 27% and 77% for the highest and lowest tertiles of posttreatment Ki67 [11] . The prognostic classifications of the Comprehensive Cancer Centre of Clermont-Ferrand, France, and of the Modena University Hospital, Italy, are indeed on the basis of a combination of post-treatment SBR or Ki-67 with residual tumour in axillary nodes [13] or in both axillary nodes and the primary tumour [14] . As proliferation is also considered as a predictive marker of chemotherapy efficacy, this type of classification may be especially useful in the near future to select patients to test non-cross-resistant adjuvant regimens. Finally, for some investigators, pre-therapeutic biomarkers, such as estrogen receptor status and nuclear grade, should also be included in a score system [8] , indicating possibly different classifications according to the molecular subtypes in the future.
This gradual improvement in pathological response classification neoadjuvant chemotherapy is illustrated by the two 4-year apart reports of this SICOG phase III study in which two different staging systems were successively used to assess the main end point. This modification also underlines weaknesses of these classifications, which have been neither firmly validated nor standardised across studies. Both classifications are probably overlapping, and many correlations exist between these different clinical, pathological and biological parameters. Nevertheless, standardisation of response criteria is required, and before accepting one of these new classifications as a primary end point, interobserver variability should be addressed and prospective validations within large independent patient data sets treated with different chemotherapy regimens are clearly needed.
Another very important point is the validation of pCR as a surrogate end point for RFS or OS. This assumption was on the basis of the observed correlation between pCR and the long-term outcome in multivariate analyses that is in fact a necessary but not sufficient prerequisite to consider response as a surrogate marker of RFS or OS. According to Prentice [15] , to be validated as a surrogate marker, pCR should also fully capture the treatment's effect on true outcome, which to our knowledge, has not been tested for. At an 'individual level' [16] , although a pCR portends a favourable outcome for most patients, some patients with pCR will experience recurrent disease. Reported series have shown 5-year recurrence rates from 13% to 25%, and in a retrospective analysis of patients treated in the MD Anderson Cancer Center, 5-year RFS rates were 91% and 84% for patients with pCR in case of HR+ or HR2 tumours [17] .
For validation of a surrogate end point at the 'trial level' [16] , a meta-analysis showing a strong relationship between odds ratio for response and hazard ratio for RFS or OS is commonly used [18] . At the present time, the number of phase III randomised studies comparing two neoadjuvant chemotherapy regimens with published data on long-term outcome is still limited (Table 1) , and only four [2, 20, 22, 27] including the study published in this issue of Annals of Oncology have reported the superiority of a treatment arm over another one both for pCR and for RFS or OS. Conversely, in the large NSABP B27 phase III study, the addition of four cycles of docetaxel (Taxotere) in a neoadjuvant setting did not improve RFS while pCR was increased from 13% to 26% (P < 0.001) [6] . An important point for this discrepancy may be the duration of neoadjuvant chemotherapy [28] [29] [30] as, according to the classic log-kill model, a longer duration of treatment would have stronger impact for eradication of large primary tumours than for treatment of micrometastases.
Finally, two recent international expert reviews [31, 32] concluded that pCR was not a robust enough surrogate marker of RFS and OS. 'Intermediate biomarker' was proposed as a preferential term [31] .
We might ask whether neoadjuvant chemotherapy should be regarded simply as an adjuvant chemotherapy proposed before surgery to women who might otherwise have required a mastectomy because of the size of the tumour. Certainly not.
In clinical practice, a potentially very useful advantage of neoadjuvant chemotherapy may be to monitor tumour response in order to tailor individual treatment on the basis of response. In the past, three randomised studies have included this information within the design of the trial [33] [34] [35] [36] .
The first prospective randomised phase III study that used response as a decision tool was carried out at MD Anderson Cancer Center from 1985 to 1989 [33] . The aim of this study was to determine whether the introduction of an adjuvant, presumed non-cross-resistant chemotherapy would improve RFS and OS rates of patients with incomplete pathological response to three cycles of a vincristine-cyclophosphamidedoxorubicin-prednisone (VCAP)-based regimen. After surgery, 106 patients who had >1 cm 3 of residual tumour in the breast were randomly assigned to receive five more cycles of the same regimen (VCAP) (n = 51) or five cycles of vinblastine, methotrexate and fluorouracil (VbMF) (n = 55). The other patients who had a pCR or <1 cm 3 residual disease received five more courses of VCAP. Among randomised patients, those who received VbMF had a trend towards improved RFS (estimated 5-year RFS 49% against 39%, P = 0.16) and OS (65% against 47%, P = 0.06). On the contrary, 5-year RFS of observational cohort of patients with pCR and <1 cm 3 residual disease was 86% and 63%, respectively. Beyond the limited size of the trial and the absence of taxane, we cannot conclude if randomised patients did gain a benefit from a non-crossresistant adjuvant chemotherapy nor if patients with limited residual disease would have benefited from the other adjuvant treatment [33] .
The other two randomised studies were slightly different in their concept [34] [35] [36] . The complete chemotherapy regimens were administered before surgery, and the main end point was assessed on surgical procedure. In the phase III Aberdeen trial carried out from 1996 to 1999, 162 patients received four neoadjuvant cycles of a cyclophosphamide-vincristinedoxorubicin-prednisone (CVAP) chemotherapy. Those who achieved a complete or partial clinical response (n = 104) were randomly assigned either to four more identical cycles (n = 50) or to four cycles of docetaxel (100 mg/m 2 every 3 weeks) (n = 47). Crossing to the docetaxel regimen resulted in a significant improvement both in the overall clinical response rate (85% against 64%, P = 0.03, in intention-to-treat analysis) and in the pCR rate (34% against 16%, P = 0.035). The 3-year disease-free survival (DFS) rate and OS were also improved (90% against 77%, P = 0.03 and 97% against 84%, P = 0.05, respectively) [20] . These last results, not published in full, should be considered with caution as the study was not statistically designed to evaluate DFS or OS. On the other hand, patients who failed to respond to the first four cycles of CVAP (n = 55) received four cycles of docetaxel in a nonrandomised fashion. Overall clinical response was 55% but only one patient achieved a pCR [34] . DFS in this group remained very low.
In the GeparTrio trial, patients received preoperatively two cycles of docetaxel-doxorubicin-cyclophosphamide (TAC). Those whose tumour size decreased by at least 50% by sonographic measurement were randomly assigned to receive four (n = 704) or six (n = 686) more identical cycles. While patients having received eight TAC had statistically significant higher sonographic response (28% against 23%, P = 0.033), the rate of breast-conserving surgery was similar in both groups. Overall, the primary end point, an increased rate of pCR in the arm treated with the higher number of TAC cycles, was not achieved (23.5% against 21.0%, P = 0.15) [36] . Non-earlyresponding patients were randomly assigned to four cycles of TAC (n = 321) or to four cycles of a less toxic combination of vinorelbine-capecitabine (NX) (n = 301). For those patients, pCR was observed in 5% and 6%, confirming initial observations. Switching patients without early response to treatment with TAC to four cycles of NX did not modify sonographic or pathological responses, confirming the end point of this study: for patients who did not respond to two cycles of TAC neoadjuvant regimen, switching to NX, a less toxic regimen, does not compromise immediate efficacy [35] . Results for DFS and OS are warranted for the two parts of the GeparTrio trial.
The results of the first two trials indicate that both responders and non-responders to CVAP may benefit from additional therapy. These results contrast with exploratory analyses of the large NSABP B27 trial in which women with operable breast cancer (n = 2411) were randomly assigned to receive preoperative doxorubicin-cyclophosphamide (AC) followed by surgery, AC followed by docetaxel (T) and surgery or AC followed by surgery and then T. The benefit of additional preoperative T for long-term outcomes was only observed in 5y DFS 48% 60% P = 0.18 5y 52% 54% P = 0.64 NSABP B27 [6] DFS and OS [2] tpCR EP · 4 (12w) wEPCis · 12 (12w) 100 100 tpCR 6% 16% P = 0.02 *5y RFS 53% 64% P = 0.11 5y OS 69% 82% P = 0.07
Results from randomised phase III studies comparing different neoadjuvant chemotherapies for which both pathological response and long-term outcome criteria are available (adapted and actualised from Bonnefoi [19] ).
a 5-year DMFS: 55% against 73% (P = 0.04); at multivariate analysis, PET independently predicted better DMFS (P = 0.018) and OS (P = 0.03), impact on RFS being of borderline significance (P = 0.057). bpCR, pathological complete response in breast; tpCR, total complete response (breast and axillary nodes); pCR, pathological complete response; y, year; Med FU, median follow-up; CVAP, cyclophosphamide, vincristine, doxorubicin, prednisone; D, docetaxel; AC, doxorubicin, cyclophosphamide; AD, doxorubicin, docetaxel; EP, epirubicin, paclitaxel; E, epirubicin; P, paclitaxel; AP, doxorubicin, paclitaxel; CAF, cyclophosphamide, doxorubicin, fluorouracil; CEF, cyclophosphamide, epirubicin, fluorouracil; ECisF, epirubicin, cisplatin, infusional fluorouracil; VE, vinorelbine, epirubicin; Tam, tamoxifen; CMF, cyclophosphamide, methotreaxate, fluorouracil; Tz, trastuzumab; EPCis, epirubicin, paclitaxel, cisplatin; DFS, disease-free survival; RFS, relapse-free survival; OS, overall survival; md fu, median follow-up; m, months; NA, not available; NS, not significant; DMFS, distant metastasis-free survival.
patients with partial tumour response to AC, without any benefit in non-responders or complete responders [6] . Unfortunately, because of the designs of all these studies, the main issue was not to validate the concept of this 'learn on the way' design [37] . At the present time, whether tailoring individual treatment according to response to neoadjuvant chemotherapy is really beneficial for patients remains to be demonstrated. Assessing such a strategy will be facilitated in the near future thanks to functional and molecular imaging that can further improve early assessment of tumour response and, above all, the development of newer therapies, including antiangiogenic therapies, with the anticipated absence of crossresistance with anthracyclines and taxanes. Furthermore, molecular analyses of post-chemotherapy surgical residual disease for proliferative factors and predictive factors may also be very informative in the future to select the most appropriate adjuvant treatment.
Despite the weakness of pCR as a surrogate marker for OS and DFS for strict comparisons of chemotherapy regimens, neoadjuvant studies are extremely useful in translational research to study in vivo the impact of systemic treatment on tumour biology, to assess potential predictive factors and to allow pharmacodynamic and pharmacogenetic substudies. They may also be very informative to test synergies of new associations. Furthermore, a new type of translational research has been recently developed for more frequent smaller tumours. In the 'biological window' design [31, 37] , very similar to a phase 0 trial, the aim is not to downstage surgery but to make use of the elapsed time between diagnostic biopsy and surgical resection to give relatively non-toxic agents in order to carry out translational research.
Regarding extensive financial and patient investment, phase III trials should be designed to positively impact clinical practice, on the basis of well-defined, widely validated, reproducible and clinically significant primary end points. As pCR after neoadjuvant chemotherapy does not fill any of these criteria, we believe that having chosen pCR as the main end point of this randomised phase III trial is suboptimal. In neoadjuvant settings, the only significant clinically demonstrated benefit may be conserving surgery and long-term DFS and OS without any validated surrogate marker. However, conserving surgery is highly influenced by surgical practice and should not be considered as a reliable end point. RFS or DFS should remain the primary end point of these randomised phase III studies.
This dose-dense cisplatin-containing regimen (PET) had previously been assessed by the SICOG in a phase II study including 68 patients with advanced breast cancer. Fourteen clinical complete responses and 19 partial responses had been observed among the 35 patients with locally advanced disease. pCR or good pathological partial response was achieved in 36% of the patients (n = 33). The authors concluded that PET administration was a 'very effective approach in advanced breast cancer patients' [38] . At that time, a strategy that could have been chosen by the authors was indicated [19] . pCR could have been chosen before as a mandatory end point of this randomised study to extend it to a large neoadjuvant/adjuvant randomised phase III study using RFS as its primary end point, in a similar design of the ongoing couple trials neoALTTO and ALTTO.
Finally, these results are very provocative and the clinical benefit is very high. Once again, they raise questions regarding the dose intensity of chemotherapy and the upfront use of platinum-based chemotherapy especially in high-grade tumours. Besides the fact that DFS was not the primary end point of the trial, the current report from Frasci et al. contains a surprisingly high number of statistical tests. Altogether, the conclusions of this study will need to be confirmed before becoming standard practice. references
